QUIA Stock Overview
Engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Quia Pharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.021 |
| 52 Week High | SEK 0.26 |
| 52 Week Low | SEK 0.018 |
| Beta | 0.72 |
| 11 Month Change | -36.14% |
| 3 Month Change | -67.97% |
| 1 Year Change | -91.67% |
| 33 Year Change | -99.98% |
| 5 Year Change | n/a |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| QUIA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -10.9% | 1.8% | 1.4% |
| 1Y | -91.7% | 31.3% | 24.5% |
Return vs Industry: QUIA underperformed the Swedish Biotechs industry which returned 30.2% over the past year.
Return vs Market: QUIA underperformed the Swedish Market which returned 24.5% over the past year.
Price Volatility
| QUIA volatility | |
|---|---|
| QUIA Average Weekly Movement | 17.2% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.8% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: QUIA's share price has been volatile over the past 3 months.
Volatility Over Time: QUIA's weekly volatility has decreased from 23% to 17% over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3 | Marcus Bosson | www.quiapeg.com |
Quia Pharma AB (publ) engages in the research, development, and commercialization of medicines based on Uni-Qleaver, a drug delivery platform. The company develops drugs through its pegylation technology platform. Its product pipeline includes QPG-1030 (pegylated teduglutide) for the treatment of short bowel syndrome, and QPG-1029 under pre-clinical development for stable plasma concentration, as well as antibody-drug conjugates being developed using the company’s Uni-Qleaver technology-platform.
Quia Pharma AB (publ) Fundamentals Summary
| QUIA fundamental statistics | |
|---|---|
| Market cap | SEK 30.54m |
| Earnings (TTM) | -SEK 13.86m |
| Revenue (TTM) | SEK 4.99m |
6.1x
P/S Ratio-2.2x
P/E RatioIs QUIA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| QUIA income statement (TTM) | |
|---|---|
| Revenue | SEK 4.99m |
| Cost of Revenue | SEK 1.30m |
| Gross Profit | SEK 3.69m |
| Other Expenses | SEK 17.55m |
| Earnings | -SEK 13.86m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0093 |
| Gross Margin | 73.94% |
| Net Profit Margin | -277.59% |
| Debt/Equity Ratio | 9.6% |
How did QUIA perform over the long term?
See historical performance and comparison